1. Immunotherapy for Lung Malignancies
Jonathan Chee, PhD, Bruce W.S. Robinson, MD, Robert A. Holt, PhD, Jenette Creaney, PhD 
CHEST 
Volume 151, Issue 4, Pages (April 2017)
DOI: /j.chest
Copyright © 2016 University of Western Australia Terms and Conditions

2. Figure 1
Tracking neoantigen-specific immune responses by enzyme-linked ImmunoSpot (ELISPOT). Representative picture of ELISPOT wells with spots that represent cells that produce interferon-γ in response to neoantigen peptide stimulation but not to the wild-type peptide sequence. Cells from tumor draining lymph nodes of five mice inoculated with the AB1-HA mesothelioma cell line were tested against predicted neoantigen-peptide-mutated Uqcrc2 (abbreviated to Uq2) and compared against wild-type Uqcrc2 peptide (left). Spots in each well are cells that respond to peptide stimulation. A dot plot quantifying the proportions of spot forming units in each well is shown on the right. MUT = mutant; WT = wild type.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 University of Western Australia Terms and Conditions

3. Figure 2
Neoantigen immunotherapy in patients. Tumor samples from patients are sequenced for mutations and have their neoantigens predicted. Neoantigen peptides are synthesized for vaccination. Enzyme-linked ImmunoSpot (ELISPOT) and multimers are used to validate neoantigen T-cell responses in patients' blood. Once validated, T-cell responses in blood can be monitored longitudinally after different immunotherapies, vaccination, or chemotherapy and correlated with clinical outcomes.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 University of Western Australia Terms and Conditions